BridgeBio Pharma (BBIO) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.81
- Estimate
- -$0.56
- Surprise
- -44.7%
- Revenue (period 2026-09-30)
- $353.2M
- Score today
- 5.8/10
Revenue source: xbrl.
How the report landed
BridgeBio Pharma (BBIO) reported a wider loss than forecast — adjusted EPS of -$0.81 against the -$0.56 estimate (a 44.7% shortfall).
Coverage in the report window
- BridgeBio Pharma Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-10-29
- BridgeBio Pharma Q3 2026 Earnings Call Transcript — benzinga, 2026-10-29
Where TrendMatrix's rating stands now
TrendMatrix currently rates BBIO Sell at 5.8/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's -44.7% surprise compares with a -41.4% four-quarter average.
What argues against it
- Concentration risk — Product: Attruby and Beyonttra
- Quality below floor (4.0 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $70.73
- Price target
- $97.03
- Stop
- $66.63
- Upside to target
- +37.2%
- Reward-to-risk
- 3.3:1
Risk check: trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
BBIO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $13.83B
- P/E (fwd)
- -314.9
- 52-week range
- $60.22–$93.42
- Off 52-week high
- 24.3%
- RSI (14)
- 70
- Volume vs avg
- 1.86×
- Score today
- 5.8/10